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Accepted 25 November 2013; Published online 20 February 2014AbstractObjective: Controversial and misleading interpretation of data from randomized trials is common. How to avoid misleading interpre-
tation has received little attention. Herein, we describe two applications of an approach that involves blinded interpretation of the results by
study investigators.
Study Design and Settings: The approach involves developing two interpretations of the results on the basis of a blinded review of the
primary outcome data (experimental treatment A compared with control treatment B). One interpretation assumes that A is the experimental
intervention and another assumes that A is the control. After agreeing that there will be no further changes, the investigators record their de-
cisions and sign the resulting document. The randomization code is then broken, the correct interpretation chosen, and the manuscript final-
ized. Review of the document by an external authority before finalization can provide another safeguard against interpretation bias.
Results: We found the blinded preparation of a summary of data interpretation described in this article practical, efficient, and useful.
Conclusions: Blinded data interpretation may decrease the frequency of misleading data interpretation. Widespread adoption of blinded
data interpretation would be greatly facilitated were it added to the minimum set of recommendations outlining proper conduct of random-
ized controlled trials (eg, the Consolidated Standards of Reporting Trials statement).  2014 The Authors. Published by Elsevier Inc.
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Open access under C1. Introduction
Interpretation of data, a vitally important part of con-
ducting research [1], is never totally objective and is there-
fore vulnerable to prior convictions, wishful thinking, and
conflict of interestdin particular, the influence of commer-
cial funding [2]. Presentations of results can be so pro-
foundly misleading that the clinical message is the
reverse of what should be conveyed [1,3e5]. One could
argue that the best way to detect and correct such bias
would be through peer-review process. The frequency of
biased interpretation in the medical literature suggests,
however, that many reviewers have the same sorts of biases
as do the original researchers. Although guides for detect-
ing bias and guides for consumers of research faced with
misleading interpretations are available [4,6], it is often
impossible to detect that the data analysis was flawed.C BY-NC-ND license. 
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 Although misleading interpretation of data (inter-
pretative bias) was formally described more than
15 years ago in a seminal article by Gotzsche,
currently there are few strategies for reducing the
risk of interpretation bias.
 This article describes the application of an
approach to execution of blinded interpretation of
research data to safeguard against interpretation
bias.
 The suggested procedure, best suited for the inter-
pretation of data of randomized controlled trials, is
simple, feasible, and efficient.In this article, we describe a modification of a previously
suggested approach to minimize the chance of mis-
leading interpretation (interpretative bias) and describe its
implementation.
1.1. Previous solutions
Gotzsche [3] first introduced the concept ‘‘interpretive
bias,’’ although the specific term was introduced subse-
quently. He proposed that the authors of clinical trials
should write two manuscripts, one assuming that treatment
A is experimental and treatment B is control, and another
article assuming the opposite (that treatment B is experi-
mental and A is control). He suggested that both manu-
scripts be completed and approved by the authors before
the randomization code is broken. Subsequently, Gotzsche
[7] also went on to use this approach and, on three occa-
sions, wrote two blinded manuscripts [8,9].
We implemented this approach in 2004 while in the pro-
cess of preparing a manuscript that dealt with alternative
approaches to eliciting patient utilities for health states
[10]. The team statistician provided complete results
labeled as group A and B; the rest of the research team
was unaware of whether group A was exposed, or not
exposed, to the marker states. One of us (H.J.S.) led us in
producing many blinded draft versions, and finally two
definitive manuscripts: One assuming that group A was
exposed to marker states, the other that group B was
exposed to marker states. We broke the code only after
agreeing that there would be no further changes to the man-
uscripts, and submitted the appropriate manuscript.
Although interesting and enlightening, we found the
approach very onerous because it involved obtaining feed-
back from all coauthors on several revised, duplicate ver-
sions (groups A and B). In the many randomized trials
our group had conducted subsequently, we have never
repeated the process.1.2. A more feasible alternative
Our next endeavor with blinded interpretation was in the
reporting of the Study to Prospectively Evaluate Reamed
Intramedually Nails in Patients With Tibial Fractures
(SPRINT) trial [11,12], a multicenter randomized con-
trolled trial (RCT) comparing the treatment of tibial shaft
fractures with reamed or unreamed intramedullary nails.
The writing committee of the trial was once again presented
with an analysis of the results as treatment A and compared
it with treatment B. Rather than writing two manuscripts,
they discussed and came to agreement as to how they
would interpret the results if treatment A proved to be re-
amed nailing and treatment B proved to be unreamed nail-
ing. They recorded their decisions as ‘‘Minutes of the
Blinded Review of the Data’’ document that was approved
by all members of the Committee (see Appendix A at www.
jclinepi.com). They then proceeded to break the randomiza-
tion code, choosing the correct interpretation, and wrote the
manuscript. The SPRINT Writing Committee members
found this approach practical, feasible, and only marginally
more time consuming than having a single interpretation.
The Finnish Degenerative Meniscal Lesion Study (FI-
DELITY) is a placeboesurgery controlled trial addressing
the efficacy of arthroscopic partial meniscectomy (APM)
in patients with degenerative meniscus lesion [13,14].
Prompted by the prior successful experience, one of the
SPRINT authors (G.H.G.) proposed that the FIDELITY in-
vestigators consider using this approach in interpreting the
data of the trial. As noted previously, the end result of the
blinded interpretation process is a document we have called
the ‘‘Minutes of the Blinded Review of the Data’’ (see
Appendix B at www.jclinepi.com).
For the FIDELITY trial, the FIDELITY Writing Com-
mittee introduced two minor modifications to the procedure
used in the SPRINT trial. First, they prepared a brief
‘‘Background assumptions’’ section and a succinct sum-
mary of the primary and secondary outcomes as well as
key statistical analyses. These modifications were prompted
by a belief that review of the theoretical basis of the trial
would facilitate an objective and enlightened interpretation
of the results. Second, to further increase the transparency
and rigor of our blinded data interpretation, the FIDELITY
Writing Committee introduced another safeguard to the
process by asking an investigator not involved in any part
of the FIDELITY trial (G.H.G.) to scrutinize our two inter-
pretations (ie, to provide an ‘‘external validation’’).
This external validation (commentary) noted that for the
primary outcome at 12 months, there was little issue: virtu-
ally no difference between groups, a conclusion that was
secure whether A or B represented the group that received
APM. The external reviewer suggested that the FIDELITY
investigators may have preferred a definitive result of no
benefit. Therefore, they were excessively inclined to dismiss
findings at 2 months that suggested a difference in both
Western Ontario Meniscal Evaluation Tool (WOMET) score
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the FIDELITY investigators should acknowledge the possi-
bility, indeed the likelihood, of transient benefit or harm
after the procedure.
This suggestionby the external reviewer (a concern that the
peer reviewers of the FIDELITY publication shared) promp-
ted the FIDELITYinvestigators to reassess both the data anal-
ysis and interpretation of the findings of our trial. In making
this reassessment, the FIDELITY investigators realized that
they had neglected differences in the WOMETand pain after
exercise scores between the two groups at baseline. An anal-
ysis adjusted for these baseline differences showed no tran-
sient 2-month APM-induced benefit in the WOMET and
pain after exercise scores. This revision reinforced the initial
interpretation of no difference between the two groups.2. Discussion
Although guides to the reporting of randomized trials
[15] and protocols for trials [16] are available, these initia-
tives focus on provision of accurate data, whereas investi-
gators have paid relatively little attentiondand provided
even fewer suggestions for safeguardsdto the risk of
misleading data interpretation. We have developed and, in
two randomized trials, implemented the blinded (treatments
A and B) preparation of a summary of data interpretation
assuming that treatment A is intervention and assuming
treatment B is intervention. We have found the approach
practical, efficient, and useful.
Our process is not the first of its kind. Pocock [17]
described a similar process when he commented on the
seminal article by Gotzsche [3] who described writing
two complete manuscripts. Pocock suggested that, rather
than writing two complete manuscripts, investigators should
provide a detailed protocol of how they will interpret the re-
sults, record any additional analyses that will be undertaken
whether experimental treatment is A or B, and then adhere
to these plans once the code is broken. He suggested that
one workable scenario would be for the primary outcomes
part of the article’s ‘‘Results’’ section to be drafted in two
versions, together with ‘‘Summary’’ and ‘‘Conclusions’’
sections to match. Only then would the code be broken, sec-
ondary analyses be carried out, and consequent ‘‘fleshing
out’’ of the manuscript be conducted. Pocock concluded
his article by suggesting that this approach carries the pros-
pect of having a manuscript made up of two parts: (1) pri-
mary results and conclusions (‘‘beyond reproach’’ arising
from blinded analysis and interpretation) and (2) secondary
results and conjecture (prone to selectivity because of un-
blinded analysis and interpretation, and to be accompanied
by a warning about potential bias).
Neither the approach suggested by Gotzsche [3] nor Po-
cock [17] has seen much usedindeed, apart from the three
articles published by Gotzsche [7e9], we know of only one
study in which either approach was implemented: our own
experiment in writing two manuscripts. The approach wehave described in this article provides a simplification to
Pocock’s proposal, further enhancing the efficiency of the
procedure and its potential attractiveness and feasibility.
Another novel aspect of the approach described in this
article is the external validation of the interpretation by
an investigator not involved in any part of the trial. In the
FIDELITY study, the external scrutiny proved important
and helpful, calling the FIDELITY investigators’ attention
to a problem in interpretation that was ultimately resolved
by a revised data analysis. Although in this case the
external validation was carried out only after the first
version of the paper was submitted for peer review, we
recommend this procedure be performed before submis-
sion. One could go further and have the entire blinded inter-
pretation done by a team of individuals separate from the
investigatorsdas is done currently for data monitoring
committees. Whether the additional safeguards against bias
would be worth the added complexity and effort of such a
procedure may warrant investigation.
What should be the next steps in reducing interpretative
bias from medical literature? The focus currently is on ob-
taining bias-free data. For example, CONSORT states as
follows (item 11a): ‘‘Unblinded data analysts may intro-
duce bias through the choice of analytical strategies, such
as the selection of favorable time points or outcomes, and
by decisions to remove patients from the analyses.’’ The
CONSORT’s intent is to provide standards for reporting,
not conduct; thus, the guidance to conduct blinded analysis,
although hard to misinterpret, remains implicit. A warning
about unblinded interpretation, parallel to the warning
about unblinded analysis, would be a worthwhile addition
to CONSORT, and could have the same effect. Such a
warning could come with a recommendation, again parallel
to the current recommendation regarding blinded analysis,
for an explicit statement about whether the authors con-
ducted blinded interpretation. Such a statement would
likely increase use of the method. An agreement among
medical scientists that the details of a separate blinded
interpretation plan (eg, as a part of statistical analysis and
interpretation plan) are registered in a publicly available
database (eg, ClinicalTrials.com) similar to the current
practice regarding other details of RCTs could also promote
increased use of blinded interpretation. Finally, post hoc
changes (eg, adjusted analyses) made after the A/B code
is broken need to be described as exploratory analyses.
Our proposal, although likely to reduce interpretation
bias, is unlikely to represent a foolproof solution. Thus, even
when authors have undertaken blinded interpretation, readers
must remain alert to the possibility of interpretation bias.Appendix
Supplementary material
Supplementary data related to this article can be found at
http://dx.doi.org/10.1016/j.jclinepi.2013.11.011.
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